Association of Tecovirimat Therapy With Mpox Symptom Improvement: A Cross-sectional Study-King County, Washington, May-October 2022.

"Potential conflicts of interest. M. R. G. has received research support from Hologic and SpeeDx. M. S. R. received research funding from Nabriva, unrelated to this work. R. A. B. I. consults for AbbVie (scientific advisory board), unrelated to this topic; receives research funding through the University of Washington from Enanta Pharmaceuticals and Ascentage Pharma, unrelated to this topic; and receives funding through the National Institutes of Health as an investigator for the STOMP trial. C. A. C. has received consultant fees from Roche Diagnostics. J. C. D. has conducted research with donated supplies from Hologic and Mayne Pharmaceuticals. E. N. K. and E. J. C received travel grants to attend ID Week. All other authors report no potential conflicts."

"Financial support. E. N. K. is supported under National Institutes of Health STD and AIDS Training grant 5T32AI007140–45. Incentives were provided by the King Holmes Endowed Professorship held by J. C. D. The REDCap instance used is supported by the Institute of Translational Health Sciences, which is funded by the National Center for Advancing Translational Sciences of the National Institutes of Health (award number UL1TR002319). All other authors participated in this work as part of their normal duties and did not receive additional funding for this work. Financial support."